Hallucinations in Parkinson's disease

被引:0
作者
Moser, A [1 ]
Hagenah, J [1 ]
Kömpf, D [1 ]
机构
[1] Med Univ Lubeck, Neurol Klin, Klinikum Schleswig Holstein, D-23538 Lubeck, Germany
来源
NERVENARZT | 2003年 / 74卷 / 04期
关键词
Parkinson's disease; hallucinations; dream activity; sleep disturbances; L-dopa; dopamine agonists; serotonin antagonists;
D O I
10.1007/s00115-003-1511-8
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
The appearance of psychiatric symptoms is not rare in the course and treatment of Parkinson's disease. In particular, therapy with L-dopa or dopamine agonists leads to increased dream activity. As with sleep disturbances, this can be a warning signal of paranoid hallucinatory psychosis. However, isolated visual hallucinations before manifest psychosis in Parkinson's must generally be regarded as resulting from medication. They occur in up to 30% of Parkinson's patients and often involve visual and figurative hallucinations. Visual hallucinations most probably result from the combined effect on dopaminergic and serotonergic systems in the CNS. Therapy consists in normalization of H2O and electrolyte levels, control of the accompanying medication, reduction of the evening doses of anti-Parkinson's medications, and serotonin antagonists such as clozapine.
引用
收藏
页码:376 / 386
页数:21
相关论文
共 23 条
  • [1] PARKINSONS-DISEASE - PATHOPHYSIOLOGY
    AGID, Y
    [J]. LANCET, 1991, 337 (8753) : 1321 - 1324
  • [2] Hallucinations, REM sleep, and Parkinson's disease - A medical hypothesis
    Arnulf, I
    Bonnet, AM
    Damier, P
    Bejjani, BP
    Seilhean, D
    Derenne, JP
    Agid, Y
    [J]. NEUROLOGY, 2000, 55 (02) : 281 - 288
  • [3] Visual hallucinations in Parkinson's disease: a review and phenomenological survey
    Barnes, J
    David, AS
    [J]. JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY, 2001, 70 (06) : 727 - 733
  • [4] David AS, 1999, NERVENHEILKUNDE, V18, P104
  • [5] Visual halluzinations in patients with PD and the Charles-Bonnet-syndrome - a phenomenological and pathogenetic confrontation
    Diederich, NJ
    Pieri, V
    Goetz, CG
    [J]. FORTSCHRITTE DER NEUROLOGIE PSYCHIATRIE, 2000, 68 (03) : 129 - 136
  • [6] Pharmacokinetic-pharmacodynamic consequences and clinical relevance of cytochrome P450 3A4 inhibition
    Dresser, GK
    Spence, JD
    Bailey, DG
    [J]. CLINICAL PHARMACOKINETICS, 2000, 38 (01) : 41 - 57
  • [7] Hallucinations in Parkinson's disease -: Prevalence, phenomenology and risk factors
    Fénelon, G
    Mahieux, F
    Huon, R
    Ziégler, M
    [J]. BRAIN, 2000, 123 : 733 - 745
  • [8] Tactile hallucinations in Parkinson's disease
    Fénelon, G
    Thobois, S
    Bonnet, AM
    Broussolle, E
    Tison, F
    [J]. JOURNAL OF NEUROLOGY, 2002, 249 (12) : 1699 - 1703
  • [9] Prospective longitudinal assessment of hallucinations in Parkinson's disease
    Goetz, CG
    Leurgans, S
    Pappert, EJ
    Raman, R
    Stemer, AB
    [J]. NEUROLOGY, 2001, 57 (11) : 2078 - 2082
  • [10] Hallucinosis in idiopathic Parkinson's disease
    Graham, JM
    Grunewald, RA
    Sagar, HJ
    [J]. JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY, 1997, 63 (04) : 434 - 440